{
  "id": 4807810,
  "title": "Symbiotec Pharmalab shares make muted debut, later gain over 8%",
  "url": "https://urgent.news/2026/09/01/symbiotec-pharmalab-shares-make-muted-debut-later-gain-over-8",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T06:52:42.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/stock-markets/symbiotec-pharmalab-shares-make-muted-debut-later-gain-over-8/article71413839.ece"
  },
  "original_language": "en",
  "account": "The initial public offering (IPO) of Symbiotec Pharmalab Ltd, a research and development-focused pharmaceutical and biotechnology company, commenced on Tuesday. The shares were listed nearly 1% lower on the BSE, starting at Rs 978.20, below the issue price of Rs 988. Throughout the trading day, the stock's price recovered the early loss and ended at Rs 1,074.05, marking an 8.70% gain. On the NSE, the stock debuted at par with the issue price of Rs 988, subsequently climbing 9.65% to reach Rs 1,083.40 by the end of trading. Symbiotec's market valuation was reported at Rs 6,965.36 crore. The IPO, which included a fresh issue of up to Rs 150 crore and an Offer For Sale (OFS) component of Rs 1,607 crore, was oversubscribed 71.26 times at the time of final bidding on Thursday. The company's IPO price band was set at Rs 938-988 per equity share. The proceeds of the fresh issue will be utilized for debt repayment and general corporate purposes. Symbiotec, based in Indore, is renowned globally for its capabilities in organic chemistry, biotechnology, and complex injectables, specializing in corticosteroid and steroidal hormone active pharmaceutical ingredients (APIs).",
  "summary": "The Indore-based pharmaceutical company’s ₹1,757-crore IPO had received strong investor demand, with subscriptions reaching 71.26 times on Thursday.",
  "key_points": [
    "Symbiotec Pharmalab shares debut nearly 1% lower at Rs 978.20",
    "Stock recovers early loss, ends 8.70% higher at Rs 1,074.05",
    "IPO oversubscribed 71.26 times, proceeds for debt repayment"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}